Aaron Koenig

Company: Delix Therapeutics

Job title: Chief Medical Officer

Seminars:

De-Risking the Translation & Early Development of Novel Neuroplastogens to the Clinic 11:30 am

Highlighting opportunity for compounds with novel neuroplasticity-promoting properties to rapidly treat MDD and other related disorders Where do these neuroplastogens live within the new and emerging landscape of novel neuropsychiatric treatments?Read more

day: Track 2 AM Day 2

Panel Discussion | Moving the Gold Standard Beyond Subjective Mood Scales & Evaluating the Potential of Surrogate Endpoints 10:15 am

What are the right endpoints to use in indications, such as substance use disorder, where a defined mood scale is not clear? Critically evaluating the value of Hamilton and MADRS scales: are there different, more objective ways of tracking the severity of various psychological illnesses? Are we close to having a surrogate in psychiatry with…Read more

day: Conference Day 2 AM

Panel Discussion | Transforming ‘Precision Neuropsychiatry’ from Idea to Realization: Are we There Yet? 8:00 am

Are we prone to have a biological marker for a psychiatric indication, and how far are we from reality of identifying best responders to a given treatment? From subtyping disorders, to combining treatments for personalization, to identifying best responders: What do we mean by ‘precision’? From evident success stories so far, what kind of data…Read more

day: Conference Day 1 AM

Workshop B: Highlighting the Value of EEGs as Translational Tools in Neuropsychiatry & Beyond 9:00 am

From efficacy to target engagement to pharmacodynamics, this workshop will delve into the wide range of possibilities that EEG biomarkers offer in the field of neuropsychiatry. Furthermore, it will explore the additional data gained from implementing EEGs in neurodevelopmental disorders, such as Angelman Syndrome and ADHD. Join this workshop to: Discuss how EEG can be…Read more

day: Pre-Conf Day B